These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35361140)

  • 21. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
    Trieu MC; Bansal A; Madsen A; Zhou F; Sævik M; Vahokoski J; Brokstad KA; Krammer F; Tøndel C; Mohn KGI; Blomberg B; Langeland N; Cox RJ;
    J Infect Dis; 2021 Feb; 223(4):589-599. PubMed ID: 33247924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays.
    Tuite AR; Fisman D; Abe KT; Rathod B; Pasculescu A; Colwill K; Gingras AC; Yi QL; O'Brien SF; Drews SJ
    Microbiol Spectr; 2022 Feb; 10(1):e0256321. PubMed ID: 35196819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined Prospective Seroconversion and PCR Data of Selected Cohorts Indicate a High Rate of Subclinical SARS-CoV-2 Infections-an Open Observational Study in Lower Saxony, Germany.
    Jonczyk R; Stanislawski N; Seiler LK; Blume H; Heiden S; Lucas H; Sarikouch S; Pott PC; Stiesch M; Hauß C; Saletti G; González-Hernández M; Kaiser FK; Rimmelzwaan G; Osterhaus A; Blume C
    Microbiol Spectr; 2022 Feb; 10(1):e0151221. PubMed ID: 35171028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies.
    Garritsen A; Scholzen A; van den Nieuwenhof DWA; Smits APF; Datema ES; van Galen LS; Kouwijzer MLCE
    Infect Dis (Lond); 2021 Jul; 53(7):498-512. PubMed ID: 33684020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools.
    Ulyte A; Radtke T; Abela IA; Haile SR; Berger C; Huber M; Schanz M; Schwarzmueller M; Trkola A; Fehr J; Puhan MA; Kriemler S
    BMJ; 2021 Mar; 372():n616. PubMed ID: 33731327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population.
    Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R
    Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan.
    Valenti L; Bergna A; Pelusi S; Facciotti F; Lai A; Tarkowski M; Lombardi A; Berzuini A; Caprioli F; Santoro L; Baselli G; Ventura CD; Erba E; Bosari S; Galli M; Zehender G; Prati D;
    Blood Transfus; 2021 May; 19(3):181-189. PubMed ID: 33539289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England.
    Wells PM; Doores KJ; Couvreur S; Nunez RM; Seow J; Graham C; Acors S; Kouphou N; Neil SJD; Tedder RS; Matos PM; Poulton K; Lista MJ; Dickenson RE; Sertkaya H; Maguire TJA; Scourfield EJ; Bowyer RCE; Hart D; O'Byrne A; Steel KJA; Hemmings O; Rosadas C; McClure MO; Capedevilla-Pujol J; Wolf J; Ourselin S; Brown MA; Malim MH; Spector T; Steves CJ
    J Infect; 2020 Dec; 81(6):931-936. PubMed ID: 33068628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroprevalence of SARS-CoV-2 (COVID-19) exposure in pet cats and dogs in Minnesota, USA.
    Dileepan M; Di D; Huang Q; Ahmed S; Heinrich D; Ly H; Liang Y
    Virulence; 2021 Dec; 12(1):1597-1609. PubMed ID: 34125647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case-Control Study of Individuals with Discrepant Nucleocapsid and Spike Protein SARS-CoV-2 IgG Results.
    Wang H; Wiredja D; Yang L; Bulterys PL; Costales C; Röltgen K; Manalac J; Yee J; Zehnder J; Shi RZ; Boyd SD; Pinsky BA
    Clin Chem; 2021 Jul; 67(7):977-986. PubMed ID: 33720347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Serological Snapshot of COVID-19 Initial Stages in Israel by a 6-Plex Antigen Array.
    Fisher M; Levy H; Fatelevich E; Afrimov Y; Ben-Shmuel A; Rosenfeld R; Noy-Porat T; Glinert I; Sittner A; Biber A; Belkin A; Bar-David E; Puni R; Levy I; Mazor O; Weiss S; Mechaly A
    Microbiol Spectr; 2021 Oct; 9(2):e0087021. PubMed ID: 34612689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay.
    McDade TW; McNally EM; Zelikovich AS; D'Aquila R; Mustanski B; Miller A; Vaught LA; Reiser NL; Bogdanovic E; Fallon KS; Demonbreun AR
    PLoS One; 2020; 15(8):e0237833. PubMed ID: 32797108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of ELISA Using Total Antibody against Plant-Expressed Recombinant Nucleocapsid Protein of SARS-CoV-2.
    Tariq M; Hur J; Seo JW; Kim DY; Yun NR; Lee YM; Bang MS; Hwang SY; Kim CM; Lee JH; Song KH; Lee H; Jung J; Park JY; Kim HB; Kim ES; Lee S; Kim DM
    Microbiol Spectr; 2021 Dec; 9(3):e0067221. PubMed ID: 34817278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal profile of antibody response to SARS-CoV-2 in patients with COVID-19 in a setting from Sub-Saharan Africa: A prospective longitudinal study.
    Gebrecherkos T; Kiros YK; Challa F; Abdella S; Gebreegzabher A; Leta D; Desta A; Hailu A; Tasew G; Abdulkader M; Tessema M; Tollera G; Kifle T; Arefaine ZG; Schallig HH; Adams ER; Urban BC; de Wit TFR; Wolday D
    PLoS One; 2022; 17(3):e0263627. PubMed ID: 35320286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study.
    Stefanelli P; Bella A; Fedele G; Pancheri S; Leone P; Vacca P; Neri A; Carannante A; Fazio C; Benedetti E; Fiore S; Fabiani C; Simmaco M; Santino I; Zuccali MG; Bizzarri G; Magnoni R; Benetollo PP; Merler S; Brusaferro S; Rezza G; Ferro A
    Clin Microbiol Infect; 2021 Apr; 27(4):633.e1-633.e7. PubMed ID: 33253941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect.
    Maine GN; Lao KM; Krishnan SM; Afolayan-Oloye O; Fatemi S; Kumar S; VanHorn L; Hurand A; Sykes E; Sun Q
    J Clin Virol; 2020 Dec; 133():104663. PubMed ID: 33161369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses.
    Gozlan Y; Reingold S; Koren R; Halpern O; Regev-Yochay G; Cohen C; Biber A; Picard O; Mendelson E; Lustig Y; Mor O
    Epidemiol Infect; 2021 Jun; 149():e153. PubMed ID: 34372950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study.
    Al-Mughales JA; Al-Mughales TJ; Saadah OI
    Front Immunol; 2021; 12():705441. PubMed ID: 34539635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The reliability of SARS-CoV-2 IgG antibody testing - a pilot study in asymptomatic health care workers in a Croatian university hospital.
    Lapić I; Rogić D; Šegulja D; Kralik Oguić S; Knežević J
    Croat Med J; 2020 Dec; 61(6):485-490. PubMed ID: 33410294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low rate of COVID-19 seroconversion in health-care workers at a Department of Infectious Diseases in Sweden during the later phase of the first wave; a prospective longitudinal seroepidemiological study.
    Rashid-Abdi M; Krifors A; Sälléber A; Eriksson J; Månsson E
    Infect Dis (Lond); 2021 Mar; 53(3):169-175. PubMed ID: 33232190
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.